Real life experience in mTOR-inhibitors after lung transplantation
S. Bos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), B. Vanaudenaerde (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), L. Dupont (Leuven, Belgium), L. Godinas (Leuven, Belgium), G. Verleden (Leuven, Belgium), R. Vos (Leuven, Belgium)
Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Bos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), B. Vanaudenaerde (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), L. Dupont (Leuven, Belgium), L. Godinas (Leuven, Belgium), G. Verleden (Leuven, Belgium), R. Vos (Leuven, Belgium). Real life experience in mTOR-inhibitors after lung transplantation. 4725
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: